Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SABSW
Upturn stock ratingUpturn stock rating

SAB Biotherapeutics Inc (SABSW)

Upturn stock ratingUpturn stock rating
$0.03
Last Close (24-hour delay)
Profit since last BUY-25%
upturn advisory
WEAK BUY
BUY since 16 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: SABSW (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $0

1 Year Target Price $0

Analysts Price Target For last 52 week
$0Target price
Low$
Current$0.03
high$

Analysis of Past Performance

Type Stock
Historic Profit -100%
Avg. Invested days 20
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio 0.09
1Y Target Price -
Price to earnings Ratio 0.09
1Y Target Price -
Volume (30-day avg) -
Beta 0.55
52 Weeks Range 0.02 - 0.15
Updated Date 06/29/2025
52 Weeks Range 0.02 - 0.15
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.29

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -11193.25%

Management Effectiveness

Return on Assets (TTM) -48.28%
Return on Equity (TTM) -92.35%

Valuation

Trailing PE 0.09
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 6435987
Shares Outstanding -
Shares Floating 6435987
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

SAB Biotherapeutics Inc

stock logo

Company Overview

overview logo History and Background

SAB Biotherapeutics, Inc. is a biopharmaceutical company developing novel immunotherapies. Founded in 2014, it focuses on using DiversitAb platform to produce human polyclonal antibodies without human donors.

business area logo Core Business Areas

  • Therapeutic Development: Developing immunotherapies for infectious diseases, autoimmune diseases, and cancer using its DiversitAbu2122 platform.
  • Contract Manufacturing: Provides contract development and manufacturing services to other companies for antibody-based therapeutics.

leadership logo Leadership and Structure

Eddie J. Sullivan, PhD is the co-founder, President and CEO. The company has a board of directors and various functional departments including R&D, Manufacturing, and Commercial.

Top Products and Market Share

overview logo Key Offerings

  • SAB-185 (COVID-19 Therapy): SAB-185 was a lead therapeutic candidate for treating COVID-19, now discontinued in favor of new targets. Competitors in the COVID-19 treatment space include Pfizer (Paxlovid), Merck (Molnupiravir), and Regeneron (Ronapreve).
  • DiversitAb Platform: A proprietary platform for producing fully-human polyclonal antibodies from transchromosomic cattle. Market share for the platform itself is difficult to define, but potential competitors are companies developing similar antibody platforms or those offering traditional antibody development services.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and long development timelines. Antibody-based therapeutics are a major growth area.

Positioning

SAB Biotherapeutics is positioned as an innovator in antibody therapeutics, particularly focusing on polyclonal antibodies produced through its DiversitAbu2122 platform. They compete with companies developing monoclonal and polyclonal antibodies, and platform technologies.

Total Addressable Market (TAM)

The total addressable market for antibody therapeutics is estimated to be in the hundreds of billions of dollars annually. SAB Biotherapeutics aims to capture a portion of this market with its innovative platform and pipeline.

Upturn SWOT Analysis

Strengths

  • Proprietary DiversitAbu2122 platform
  • Ability to produce fully-human polyclonal antibodies
  • Potential for rapid response to emerging infectious diseases
  • Experienced management team

Weaknesses

  • Limited number of products in clinical trials
  • Reliance on a single platform technology
  • High cash burn rate
  • Dilution of stock

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion into new therapeutic areas
  • Increased demand for antibody-based therapies
  • Government funding for pandemic preparedness

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from established pharmaceutical companies
  • Technological advancements in alternative therapeutic modalities

Competitors and Market Share

competitor logo Key Competitors

  • LLY
  • AZN
  • REGN

Competitive Landscape

SAB Biotherapeutics faces intense competition from large pharmaceutical companies with greater resources and established market presence. Its DiversitAb platform offers a potential competitive advantage, but the company needs to demonstrate clinical efficacy and secure commercial partnerships.

Growth Trajectory and Initiatives

Historical Growth: Growth was primarily driven by government contracts and research grants. The stock has been delisted from NASDAQ.

Future Projections: Future growth is highly uncertain given the company's financial position and its delisted status. Any projections would be speculative without more recent information.

Recent Initiatives: Recent initiatives are not publicly available due to the company's current status. Historically initiatives were centered around advancing its pipeline of antibody therapeutics and securing partnerships.

Summary

SAB Biotherapeutics has an innovative antibody platform but faces significant challenges. A strength is its DiversitAb platform for polyclonal antibody generation. A weakness is its delisted status and unprofitability. It needs to secure further funding and demonstrate clinical success. The future of the company appears uncertain, especially now that it is delisted.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC Filings (historical)
  • Company Website (historical)
  • Industry Reports
  • News Articles
  • Delisting information

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. The analysis is based on publicly available information and may not be complete or accurate. The delisted status of SAB Biotherapeutics significantly impacts the reliability and completeness of available information.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About SAB Biotherapeutics Inc

Exchange NASDAQ
Headquaters Miami Beach, FL, United States
IPO Launch date 2021-02-09
CEO & Executive Chairman Mr. Samuel J. Reich
Sector Healthcare
Industry Biotechnology
Full time employees 63
Full time employees 63

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.